Palo Capital’s Alaunos Therapeutics TCRT Stock Holding History

Palo Capital’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-425	Closed	-$350K	–	195
2016 Q2	$350K	Buy	+425	New	+$463K	0.12%	194

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BGA

Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Palo Capital's TCRT Position: Q3 2016 in Review

Palo Capital sold out of Alaunos Therapeutics (TCRT) in Q3 2016, closing a stake of 425 shares — an estimated $350K sold.

Palo Capital first reported a position in TCRT in Q2 2016 and held it in 1 quarter. The position peaked at $350K in Q2 2016. 140 funds tracked by Wall St. Rank hold TCRT as of Q3 2016.

Palo Capital reported no remaining Alaunos Therapeutics position as of Q3 2016 after selling out during the quarter.
Palo Capital sold 425 Alaunos Therapeutics shares in Q3 2016, an estimated $350K.
Palo Capital first reported a position in Alaunos Therapeutics in Q2 2016 and held it in 1 quarter.
Palo Capital's Alaunos Therapeutics position peaked at $350K in Q2 2016.
140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2016.

Based on Palo Capital's 13F filing for Q3 2016, filed 20 Oct 2016.